Webb J R
Br Med J (Clin Res Ed). 1986 Apr 19;292(6527):1045-7. doi: 10.1136/bmj.292.6527.1045.
Ten patients with asthma were treated with different doses of oral corticosteroids during three separate exacerbations. Prednisolone was given in doses of 0.2, 0.4, and 0.6 mg/kg body weight daily for two weeks in a double blind randomised order (equivalent to 14, 28, and 42 mg of prednisolone daily in a person weighing 70 kg). Patients developing an exacerbation recorded peak expiratory flow rate twice daily for two days before starting and two weeks during treatment. A dose response was shown that was significant for the difference between the peak flows, low dose less than medium dose (p less than 0.005), medium dose less than high dose (p less than 0.001) at the end of treatment. These results confirm the value of treatment with oral corticosteroids in exacerbations of asthma not requiring admission to hospital and indicate that a short high dose course of corticosteroids should consist of a minimum dose of 0.6 ng prednisolone/kg body weight for a period up to two weeks.
十名哮喘患者在三次不同的病情加重期间接受了不同剂量的口服皮质类固醇治疗。在双盲随机顺序下，给予患者每日0.2、0.4和0.6毫克/千克体重的泼尼松龙，持续两周（相当于体重70千克的人每日14、28和42毫克泼尼松龙）。病情加重的患者在开始治疗前两天和治疗期间两周内每天记录两次呼气峰值流速。结果显示出剂量反应，治疗结束时，低剂量组与中剂量组之间的呼气峰值流速差异显著（p小于0.005），中剂量组与高剂量组之间差异显著（p小于0.001）。这些结果证实了口服皮质类固醇在无需住院的哮喘病情加重治疗中的价值，并表明短期高剂量皮质类固醇疗程应包括至少0.6毫克泼尼松龙/千克体重，持续时间最长为两周。
